NICE Seeks More Data From Abbott On Humira In Psoriatic Arthritis
This article was originally published in The Pink Sheet Daily
U.K. agency’s preliminary appraisal on cost effectiveness does not call for recommending adalimumab.
You may also be interested in...
U.K. agency reverses unfavorable preliminary opinions based on submissions from Roche and Abbott.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.